A production line of Wegovy injection pens for the Asian market at the Novo Nordisk A/S pharmaceutical manufacturing facility in Hillerod, Denmark, on Wednesday, Nov. 27, 2024.
Bloomberg | Bloomberg | Getty Images
One interpretation of the law of supply and demand is that when demand outstrips supply, scammers get busy. That’s certainly the case with the super-popular weight-loss drugs from Eli Lilly and Novo Nordisk.
As millions of Americans are prescribed injectable Ozempic and Mounjaro to treat type 2 diabetes, and Wegovy and Zepbound for obesity — and countless more without prescriptions seek them as “vanity drugs” to shed unwanted pounds — the manufacturers can’t keep up production. The GLP-1s, as they’re known, are pricey, too, and insurance often doesn’t cover them, provided consumers can find them.
That confluence of factors has laid the groundwork not only for a confusing online marketplace for compounded versions of the drugs — allowed by the Food and Drug Administration when proprietary ingredients are …